Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients

British Journal of Cancer

Volumn 100, Issue 3, 2009, Pages 494-500

  Van Nes, J G H ^a   Smit, V T H B M ^a   Putter, H ^a   Kuppen, P J ^a   Kim, S J ^b   Daito, M ^c   Ding, J ^c   Shibayama, M ^c   Numada, S ^c   Gohda, K ^c   Matsushima, T ^c   Ishihara, H ^c   Noguchi, S ^b   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; Cyclin dependent kinase (CDK); Distant recurrence prediction

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER TISSUE; CAUCASIAN; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE FREE INTERVAL; EARLY CANCER; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION STUDY;

ADULT; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 59649105216     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604870     Document Type: Article

References (26)

1. Altman DG, Machin D, Bryant TN, Gardner MJ (2000) Statistics with Confidence. British Medical Journal Books: Bristol
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
3. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N (2008) uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45: 31-45
4. Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F (1999) Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 17: 3048-3057
5. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26: 729-735
6. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48: 1194-1197
7. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
8. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634-1637
9. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817
10. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144
11. Gramlich TL, Fritsch CR, Maurer D, Eberle M, Gansler TS (1994) Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 3: 255-259
12. Harbeck N, Kates RE, Schmitt M (2002) Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000- 1007
13. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312
14. Ishihara H, Yoshida T, Kawasaki Y, Kobayashi H, Yamasaki M, Nakayama S, Miki E, Shohmi K, Matsushima T, Tada S, Torikoshi Y, Morita M, Tamura S, Hino Y, Kamiyama J, Sowa Y, Tsuchihashi Y, Yamagishi H, Sakai T (2005) A new cancer diagnostic system based on a CDK profiling technology. Biochim Biophys Acta 1741: 226-233
15. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H, Noguchi S (2008) Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 19: 68-72
16. Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H, Shimada M, Nakano S, Kusano C, Baba M, Takao S, Aikou T (2000) Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res 20: 1933-1937
17. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P (1999) Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA 281: 1586
18. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
19. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26: 2389-2430
20. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296
21. Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E (2000) Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110
22. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26: 721-728
23. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB (1997) Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 28: 285-309
24. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I (2000) Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156: 585-594
25. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers EJTh, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
26. van Diest PJ, Michalides RJ, Jannink L, van d V, Peterse HL, de Jong JS, Meijer CJ, Baak JP (1997) Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150: 705-711